Aptorum Group Ltd Cl A (APM)

Jan 8, 2025, 11:30 AM EST - 3 months ago

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Jan 2, 2025, 10:55 AM EST - 3 months ago

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Dec 20, 2024, 4:00 PM EST - 3 months ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Apr 30, 2024, 9:15 AM EDT - 1 year ago

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Dec 22, 2023, 4:30 PM EST - 1 year ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Dec 21, 2023, 4:30 PM EST - 1 year ago

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Nov 16, 2023, 11:00 AM EST - 1 year ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aug 10, 2023, 2:57 AM EDT - 1 year ago

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Jun 22, 2023, 8:00 AM EDT - 1 year ago

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Jun 9, 2023, 4:30 PM EDT - 1 year ago

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

May 5, 2023, 4:31 PM EDT - 2 years ago

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

May 1, 2023, 8:00 AM EDT - 2 years ago

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Apr 28, 2023, 9:44 AM EDT - 2 years ago

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Mar 17, 2023, 8:15 AM EDT - 2 years ago

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ASPI

Mar 3, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Mar 3, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Mar 2, 2023, 7:30 AM EST - 2 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Feb 10, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Feb 6, 2023, 10:08 AM EST - 2 years ago

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Jan 20, 2023, 8:22 AM EST - 2 years ago

Aptorum Group Announces 1-for-10 Reverse Stock Split

Jan 4, 2023, 9:00 AM EST - 2 years ago

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Dec 22, 2022, 8:00 AM EST - 2 years ago

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Dec 16, 2022, 8:00 AM EST - 2 years ago

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Dec 9, 2022, 7:00 AM EST - 2 years ago

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Nov 25, 2022, 8:30 AM EST - 2 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Nov 25, 2022, 8:00 AM EST - 2 years ago

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Nov 18, 2022, 5:30 PM EST - 2 years ago

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Nov 8, 2022, 6:00 AM EST - 2 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Sep 30, 2022, 7:42 PM EDT - 2 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Sep 15, 2022, 8:07 AM EDT - 2 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Sep 15, 2022, 7:00 AM EDT - 2 years ago

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Aug 25, 2022, 8:31 PM EDT - 2 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

May 17, 2022, 8:13 AM EDT - 3 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

May 2, 2022, 8:00 AM EDT - 3 years ago

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

Apr 29, 2022, 4:00 PM EDT - 3 years ago

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

Apr 25, 2022, 9:30 AM EDT - 3 years ago

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Apr 22, 2022, 8:00 AM EDT - 3 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Feb 11, 2022, 3:09 PM EST - 3 years ago

Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies

Jan 20, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Jan 18, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

Jan 10, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

Dec 3, 2021, 8:00 AM EST - 3 years ago

Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

Oct 19, 2021, 8:00 AM EDT - 3 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

Oct 15, 2021, 8:00 AM EDT - 3 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S.

Sep 15, 2021, 9:26 AM EDT - 3 years ago

Aptorum To Start Testing SACT-1 In Neuroblastoma Patients

Sep 15, 2021, 8:00 AM EDT - 3 years ago

Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma